retatrutide diabetes type 2 Helped Adults With or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds Retatrutide as a Novel Treatment

Tirzepatide, a dual GIP and GLP-1 agonist, reported roughly 15% to 20.9% depending on the arm

16 A challenge of comparing data between CVOTs is the inconsistency in the protocols for accurately detecting retinal changes

This publication has not received compensated access to Omzo's platform, has not undergone a telehealth consultation through Omzo, has not been granted access to internal clinical protocols or pharmacy sourcing documentation, and has not conducted independent testing of any Omzo medication or program component

Stomach problems, sometimes severe, have been reported in people who use Tirzepatide

Some individuals also report clear thinking and better concentration, while others note brain fog or fatigue, which may be related to low blood sugar levels (hypoglycemia)